Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in European Journal of Surgical Oncology
- Vol. 46 (6), 1124-1130
- https://doi.org/10.1016/j.ejso.2020.02.033
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Pfizer
- Bayer
This publication has 23 references indexed in Scilit:
- Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”Annals Of Oncology, 2018
- Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib eraBritish Journal of Surgery, 2018
- The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) studyVirchows Archiv, 2018
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studiesCancer Epidemiology, 2016
- Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinibBritish Journal of Surgery, 2015
- Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma groupBMC Cancer, 2014
- Gastrointestinal Stromal TumorsGastroenterology Clinics of North America, 2013
- Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of ImatinibAnnals of Surgical Oncology, 2012
- Surgical management of rectal gastrointestinal stromal tumorsJournal of Surgical Oncology, 2012
- Gastrointestinal stromal tumors: Pathology and prognosis at different sitesSeminars in Diagnostic Pathology, 2006